0      0

134 - The Use of Estrogen Therapy in Pelvic Floor Disorders

‐ Nov 1, 2014 11:00am

The cause of pelvic floor disorders is often multifactorial, requiring a multidisciplinary approach. This lecture touches on one aspect of dysfunction, estrogen deprivation. Discussion is targeted at informing the participant on the role of estrogen loss and estrogen therapy options available to minimize the consequences of pelvic floor disorders.

Contact hours available until 11/3/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:

Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation

Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab

There are no other disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.


• Describe the clinical exam findings of the patient with PFD that may benefit from estrogen therapy.
• Describe the symptoms and specific PFDs that occur in the peri and post-menopausal woman.
• List the prescription and non-prescription hormonal options for the treatment of PFDs.


You must be logged in and own this session in order to post comments.